EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence, Determinants and Outcomes of Intravenous-to-Oral Switch of Antibiotic Therapy in Hospitalized Adults With Bloodstream Infection: Secondary Analysis of a Multicenter Cohort

Lea A Nikolai iD, Beryl P Gladstone iD, Sarah V Walker iD, Jörg J Vehreschild iD, Kristina Schmauder iD, Simone Eisenbeis, Alexander Mischnik iD, Evelyn Kramme iD, Christine Geffers iD, Siegbert Rieg iD, Trinad Chakraborty iD, Maria J G T Vehreschild iD und 8 weitere

Open Forum Infectious Diseases · 31.10.2026 · 13 (11)

DOI: 10.1093/ofid/ofag666 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 19.10.2026. Verfasst von Lea A Nikolai und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Centre for Infection Research, BLOOMY.COM project, BLOOMY-PREDICT project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intravenous-to-oral switch (IVOS) is considered safe in selected patients with bloodstream infection (BSI) and provides operational advantages. Still, it is underused in many clinical settings. We evaluated IVOS patterns, associated factors, and clinical outcomes in patients with BSI.

Methods

Secondary data were analyzed from 2 prospective, multicenter cohort studies recruiting patients with BSI. IVOS was assessed on day 3 and 7 after positive blood culture. Eligibility for IVOS was based on infectious focus, clinical safe-switch criteria, and antimicrobial susceptibility. Risk factors for non-IVOS were studied using multivariable logistic regression.

Results

Among 3824 patients, 2770 were included in the secondary analysis, and 742 (19.4%) were eligible and evaluable for IVOS. By day 7, 240 patients (32.3%) underwent IVOS. Switch occurred on the day of discharge in 107 patients (44.6%), and 1 day before discharge in 46 (19.2%). The most commonly used oral agents were ciprofloxacin (75 patients [31.3%]), sultamicillin (56 [23.3%]), and cefuroxime axetil (27 [11.3%]). Barriers to IVOS on multivariable analysis included diabetes (odds ratio, 0.57 [95% confidence interval, .38–.88]; P = .01), chronic kidney disease (0.64 [.41–.99]; P = .048), Pitt bacteremia score ≥2 on day 3 (0.43 [.19–.97]; P = .04), and septic shock before day 7 (0.31 [.11–.87]; P = .03), while urogenital focus (2.22 [1.50–3.28]; P < .001) and 2 study centers were positively associated with IVOS. IVOS was associated with shorter length of stay (7 vs 12 days; P < .001) and a lower 28-day mortality rate.

Conclusions

In clinically stable patients with BSI, IVOS was infrequently implemented. Barriers to IVOS should be addressed as part of antimicrobial stewardship programs.

Schlagwörter

Stichwörter der Autor:innen

antimicrobial stewardshipbloodstream infectionintravenous-to-oral switchoral antibioticsrational antibiotic use

Autor:innen und Institutionen

  • Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany.
  • DZIF-Clinical Research Unit, Infectious Diseases, Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany.
  • DZIF German Center for Infection Research, Braunschweig, Germany.
  • Institute for Medical Microbiology, Immunology, and Hygiene, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Goethe University Frankfurt, Faculty of Medicine, Institute for Digital Medicine and Clinical Data Sciences, Frankfurt/Main, Germany.
  • Institute of Medical Microbiology and Hygiene, University Hospital Tübingen, Tübingen, Germany.

ORCID-Profile: Lea A Nikolai, Beryl P Gladstone, Sarah V Walker, Jörg J Vehreschild, Kristina Schmauder, Alexander Mischnik, Evelyn Kramme, Christine Geffers, Siegbert Rieg, Trinad Chakraborty, Maria J G T Vehreschild, Harald Seifert, Jan Rupp, Winfried V Kern, Evelina Tacconelli, Daniel Hornuss, Siri Göpel

Förderung

  • German Centre for Infection Research
  • BLOOMY.COM project
  • BLOOMY-PREDICT project
  • DZIF–Clinical Research Unit

Zitieren

APA

Nikolai, L. A., Gladstone, B. P., Walker, S. V., Vehreschild, J. J., Schmauder, K., Eisenbeis, S., Mischnik, A., Kramme, E., Geffers, C., Rieg, S., Chakraborty, T., Vehreschild, M. J. G. T., Seifert, H., Rupp, J., Peter, S., Kern, W. V., Tacconelli, E., Hornuss, D., Göpel, S., & DZIF BLOOMY study group (2026). Prevalence, Determinants and Outcomes of Intravenous-to-Oral Switch of Antibiotic Therapy in Hospitalized Adults With Bloodstream Infection: Secondary Analysis of a Multicenter Cohort. Open Forum Infectious Diseases, 13(11). https://doi.org/10.1093/ofid/ofag666

Vancouver

Nikolai LA, Gladstone BP, Walker SV, Vehreschild JJ, Schmauder K, Eisenbeis S, et al. Prevalence, Determinants and Outcomes of Intravenous-to-Oral Switch of Antibiotic Therapy in Hospitalized Adults With Bloodstream Infection: Secondary Analysis of a Multicenter Cohort. Open Forum Infectious Diseases. 2026;13(11). doi:10.1093/ofid/ofag666

BibTeX
@article{Nikolai2026,
  author = {Nikolai, Lea A and Gladstone, Beryl P and Walker, Sarah V and Vehreschild, Jörg J and Schmauder, Kristina and Eisenbeis, Simone and Mischnik, Alexander and Kramme, Evelyn and Geffers, Christine and Rieg, Siegbert and Chakraborty, Trinad and Vehreschild, Maria J G T and Seifert, Harald and Rupp, Jan and Peter, Silke and Kern, Winfried V and Tacconelli, Evelina and Hornuss, Daniel and Göpel, Siri and DZIF BLOOMY study group, DZIF BLOOMY study group},
  title = {Prevalence, Determinants and Outcomes of Intravenous-to-Oral Switch of Antibiotic Therapy in Hospitalized Adults With Bloodstream Infection: Secondary Analysis of a Multicenter Cohort},
  journal = {Open Forum Infectious Diseases},
  year = {2026},
  volume = {13},
  number = {11},
  doi = {10.1093/ofid/ofag666}
}
Kostenlos starten →